The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,788.50
Bid: 1,788.50
Ask: 1,789.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Dec 2018 16:35

RNS Number : 3061K
GlaxoSmithKline PLC
12 December 2018
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharma Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

9 (partnership shares)

£14.9439

9 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

18 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQLLFFVLFXFBZ
Date   Source Headline
22nd Dec 20212:57 pmRNSDirector/PDMR Shareholding
21st Dec 20217:00 amRNSViiV Healthcare announces FDA approval of Apretude
20th Dec 20217:00 amRNSConsumer Healthcare Chair Designate appointed
17th Dec 202112:48 pmRNSXevudy approved in Europe to treat COVID-19
15th Dec 20217:00 amRNSGSK/Sanofi COVID-19 vaccine booster & Ph3 update
13th Dec 202111:25 amRNSDirector/PDMR Shareholding
9th Dec 20214:35 pmRNSDirector/PDMR Shareholding
7th Dec 202112:00 pmRNSMedicago/GSK COVID-19 vaccine positive Ph3 data
7th Dec 20217:07 amRNSSotrovimab retains its activity vs Omicron variant
2nd Dec 20217:02 amRNSSotrovimab retains its activity vs Omicron variant
1st Dec 202111:05 amPRNTotal Voting Rights
24th Nov 20214:17 pmRNSDirector/PDMR Shareholding
24th Nov 20214:00 pmRNSGSK publishes provisional 2022 dividend dates
23rd Nov 20213:06 pmRNSDirector/PDMR Shareholding
17th Nov 20217:00 amRNSNucala approved in Europe for more indications
15th Nov 20214:37 pmRNSBlock listing Interim Review
12th Nov 202112:00 pmRNSPhase III IM administration data for sotrovimab
12th Nov 20219:23 amRNSDirector/PDMR Shareholding
10th Nov 202111:28 amRNSDirector/PDMR Shareholding
5th Nov 20215:33 pmRNSGSK shares positive Phase III data for daprodustat
1st Nov 20215:11 pmRNSTotal Voting Rights
27th Oct 20212:23 pmRNSDirector/PDMR Shareholding
27th Oct 202112:00 pmRNS3rd Quarter Results
27th Oct 20219:00 amRNSDirectorate Change
15th Oct 20212:41 pmRNSDirector/PDMR Shareholding
14th Oct 20214:31 pmRNSDirector/PDMR Shareholding
14th Oct 20214:28 pmRNSDirector/PDMR Shareholding
13th Oct 20211:55 pmRNSDirector/PDMR Shareholding
12th Oct 20213:17 pmRNSDirector/PDMR Shareholding
12th Oct 20211:36 pmRNSDirector/PDMR Shareholding
12th Oct 20211:33 pmRNSDirector/PDMR Shareholding
12th Oct 20211:30 pmRNSDirector/PDMR Shareholding
12th Oct 20211:28 pmRNSDirector/PDMR Shareholding
1st Oct 202111:54 amRNSTotal Voting Rights
24th Sep 20215:28 pmRNSDirector/PDMR Shareholding
22nd Sep 20213:58 pmRNSDirector/PDMR Shareholding
20th Sep 20212:42 pmRNSDirector Declaration
13th Sep 20215:26 pmRNSDirector/PDMR Shareholding
9th Sep 20214:42 pmRNSDirector/PDMR Shareholding
7th Sep 20214:54 pmRNSDirector/PDMR Shareholding
3rd Sep 20219:32 amRNSDirector/PDMR Shareholding
1st Sep 202111:44 amRNSTotal Voting Rights
31st Aug 20217:00 amRNSSK bio & GSK start Ph3 Covid-19 vaccine trial
25th Aug 20212:01 pmRNSDirector/PDMR Shareholding
23rd Aug 20214:39 pmRNSDirector/PDMR Shareholding
13th Aug 20219:38 amRNSDirector/PDMR Shareholding - amendment
11th Aug 20212:18 pmRNSDirector/PDMR Shareholding
11th Aug 202112:34 pmRNSDirector/PDMR Shareholding
5th Aug 20219:00 amRNSBlock Listing Application
2nd Aug 20212:23 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.